DCVC Bio is a venture capital fund that invests in early-stage life science companies driven by deep-tech approaches.
Key people at DCVC Bio.
Key people at DCVC Bio.
# DCVC Bio: Accelerating Deep-Tech Life Science Innovation
DCVC Bio is a leading venture capital firm focused on early-stage life science companies that leverage deep-tech approaches—especially artificial intelligence, computational biology, and advanced engineering—to solve some of the world’s most pressing challenges. Its mission is to back visionary scientific teams developing breakthroughs in human health, sustainable food, climate resilience, and industrial transformation. The firm’s investment philosophy centers on supporting foundational platforms rather than single-product bets, prioritizing companies that use computation to unlock new categories of therapies, materials, and agricultural solutions. DCVC Bio’s portfolio spans therapeutics, synthetic biology, agtech, and climate tech, making it a pivotal force in shaping the next generation of biotech startups. Its impact is evident in both the scientific advances of its portfolio companies and the broader ecosystem’s shift toward data-driven, scalable life science innovation.
Founded in 2018 as a specialized arm of DCVC (Data Collective), DCVC Bio was established by a group of deep-tech investors and scientists with backgrounds in AI, biotechnology, and operational leadership. The founding managing partners—Dr. John Hamer, Dr. Kiersten Stead, Matt Ocko, and Zachary Bogue—recognized the convergence of computational power and biological discovery as a historic opportunity. Their vision was to create a fund that could bridge the gap between cutting-edge science and commercialization, supporting entrepreneurs who were building not just new drugs, but entirely new platforms for biological innovation. Over the years, DCVC Bio has evolved from a niche deep-tech investor into one of the most influential biotech VCs, raising $400 million for its third fund in 2024—oversubscribed and ahead of its original target—amid a challenging fundraising environment for biotech.
DCVC Bio is riding the wave of the “bio-digital convergence”—the fusion of biology, AI, and engineering that is transforming life sciences. The timing is critical: advances in machine learning, synthetic biology, and automation are making it possible to design and test biological solutions at unprecedented speed and scale. Market forces, including rising demand for sustainable food, climate-resilient agriculture, and precision medicine, are accelerating the need for deep-tech life science innovation. DCVC Bio’s influence extends beyond its portfolio, helping to shape the ecosystem by setting new standards for what’s possible in biotech investing and encouraging a shift toward platform-based, scalable solutions. As the line between biology and technology continues to blur, DCVC Bio is positioned at the forefront of this transformation.
DCVC Bio’s future is bright, with its latest $400 million fund poised to accelerate the next wave of deep-tech life science breakthroughs. The firm will likely continue to back companies at the intersection of AI and biology, expanding into new frontiers like climate-resilient agriculture, next-generation therapeutics, and sustainable materials. Trends such as the democratization of AI, the rise of synthetic biology, and increasing urgency around climate and health challenges will shape DCVC Bio’s journey, amplifying its influence on both the startup ecosystem and the broader scientific community. As the world faces ever more complex problems, DCVC Bio’s mission—to back visionary teams using deep tech to solve hard problems—will remain more relevant than ever.
